Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
The DOI matches its Crossref record; 189 of the 189 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder associated with a significant degree of functional disability and poor quality of life. Pharmacotherapy may have a substantial impact on the course and outcome of OCD. METHOD: We review the evidence supporting available strategies for the pharmacological treatment of OCD. RESULTS: Selective serotonin reuptake inhibitors (SSRIs) remain the pharmacological treatment of choice and are associated with improved health-related quality of life. Discontinuation is associated with relapse and loss of quality of life, implying treatment should continue long-term. A substantial minority of patients who fail to respond to SSRI may benefit from dose elevation or adjunctive antipsychotics, though long-term trials validating the effectiveness and tolerability of these strategies are relatively lacking. CONCLUSION: The pharmacological evidence-base for the treatment of OCD is becoming increasingly robust. Treatment with SSRIs and clomipramine remains uncontroversial and improvements are sustained over time. Newer compounds targeting serotonin receptor subtypes and other neurotransmitter systems are undergoing evaluation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“they continue to be limited by low remission (12–16) and high relapse rates (17, 18)”
In the citing paper
“Clomipramine has a less favorable side-effect profile than SSRIs [23].”
From Clinical Advances in Treatment Strategies for Obsessive-compulsive Disorder in Adults (2023) · cites this paper as [23]
In the citing paper
“The main pharmacological treatment for OCD are antidepressant drugs, including selective serotonin reuptake inhibitors (SSRIs) (Fineberg et al., 2013).”
From The role of habit in compulsivity (2016) · cites this paper as Fineberg et al., 2013
Citations
Cites
Journal of Clinical Psychiatry
(2018) · Journal of Clinical Psychiatry · doi:10.5505/kpd · Cited by 13,651
Lifetime Prevalence of Specific Psychiatric Disorders in Three Sites
Robins, L. N. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790210031005 · Cited by 2,550 · cited 2×
“Epidemiological surveys using Diagnostic and Statistical Manual of Mental Disorders third edition, third revised edition and fourth edition (DSM-III, DSM-III-R and DSM-IV) criteria suggest lifetime prevalence to range between 1% and 3% of the worldwide population (Robins et al., 1984; Weissman et al., 1994; Wittchen a…”
BackgroundMethodChildren's Yale-Brown Obsessive Compulsive Scale: Reliability and Validity
SCAHILL, L., RIDDLE, M. A., McSWIGGIN-HARDIN, M., ORT, S. I., KING, R. A., GOODMAN, W. K., CICCHETTI, D., & LECKMAN, J. F. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199706000-00023 · Cited by 2,045 · cited 1×
“From weeks 1 to 6 and at the 10-week end point, there was significant improvement on the Children’s Yale–Brown Obsessive-Compulsive Scale (CY-BOCS; Scahill et al., 1997).”
MethodSize and burden of mental disorders in Europe—a critical review and appraisal of 27 studies
Wittchen, H.-U., & Jacobi, F. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.012 · Cited by 1,503 · cited 1×
“…and Statistical Manual of Mental Disorders third edition, third revised edition and fourth edition (DSM-III, DSM-III-R and DSM-IV) criteria suggest lifetime prevalence to range between 1% and 3% of the worldwide population (Robins et al., 1984; Weissman et al., 1994; Wittchen and Jacobi, 2005).”
BackgroundPractice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028 · cited 4×
“Recent guidelines (Greist et al., 2003; Koran et al., 2007) recommend continuation of pharmacotherapy for a minimum of 1–2 years in treatment-responsive individuals and emphasise the importance of long-term treatment from the outset.”
BackgroundMethodInfluential(2008) · Cited by 889
The Cross National Epidemiology of obsessive-compulsive disorder
Weisman, M. M., Bland, R. C., CANINO, G. J., Greenwald, S., Hwu, H., Lee, C. K., Newman, S. C., Browne, M. A. O., Rubio-Stipec, M., WICKRAMARATNE, P. J., et al. (1994) · Max Planck Institute for Plasma Physics · Cited by 688
Probing compulsive and impulsive behaviors, from animal models to endophenotypes: A narrative review
Fineberg, N. A., Potenza, M. N., Chamberlain, S. R., Berlin, H. A., Menzies, L., Bechara, A., Sahakian, B. J., Robbins, T. W., Bullmore, E. T., & Hollander, E. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.185 · Cited by 654 · cited 1×
“Other neurotransmitters such as dopamine, noradrenaline and glutamate (Fineberg et al., 2010) are also likely to be involved.”
BackgroundSelf-citationA 40-Year Follow-up of Patients With Obsessive-compulsive Disorder
Skoog, G., & Skoog, I. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.2.121 · Cited by 632
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617 · cited 1×
“The British Association for Psychopharmacology (Baldwin et al., 2005) suggest starting at the lowest efficacious dose, waiting for up to 12 weeks before evaluating effectiveness and, in the face of insufficient clinical response, upwards dose titration.”
BackgroundSelf-citationSelective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574 · cited 1×
“Treatment responders, on uncontrolled SRI, from acutephase studies, have been followed for up to 2 years without tolerance developing (Cottraux et al., 1990; Katz et al., 1990; Rasmussen et al., 1997; Rosenbaum et al., 1998; Tollefson et al., 1994; Wagner et al., 1999).”
BackgroundMcDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571 · cited 1×
“McDougle et al. (2000) reported the first double-blind, placebo-controlled study showing efficacy for risperidone in 36 patients unresponsive to 12 weeks of SRI.”
BackgroundMcDougle, C. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040046006 · Cited by 570 · cited 1×
“Again, a preferential response was seen in patients with comorbid tics (McDougle et al., 1994).”
BackgroundGreist, J. H. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950130053006 · Cited by 500 · cited 2×
“The dose–response relationship is less clear-cut for sertraline and citalopram (Greist et al., 1995a; Montgomery et al., 2001; Ushijima et al., 1997).”
BackgroundClomipramine Treatment of Obsessive-Compulsive Disorder: I. A Controlled Clinical Trial
Thorén, P. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780240079009 · Cited by 497 · cited 1×
“Similarly, superiority for clomipramine was demonstrated in head-to-head comparisons with imipramine (Foa et al., 1987; Volavka et al., 1985), nortryptline (Thoren et al., 1980) and clorgylline (Insel et al., 1983).”
BackgroundAbramowitz, J. S. (1997) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.65.1.44 · Cited by 490 · cited 2×
“Subsequent metaanalyses comparing RCTs of SRI and psychological interventions (Abramowitz, 1997; Kobak et al., 1998) also reported an apparent superiority in efficacy for clomipramine over SSRIs, other than fluoxetine or fluvoxamine, even when certain potentially confounding variables were controlled for; and superior…”
BackgroundMarch, J. S., Biederman, J., Wolkow, R., Safferman, A., Mardekian, J., Cook, E. H., Cutler, N. R., Dominguez, R., Ferguson, J., Muller, B., et al. (1998) · JAMA · doi:10.1001/jama.280.20.1752 · Cited by 469 · cited 1×
“In a cohort of 107 children and 80 adolescents, March et al. (1998) found a significant advantage for sertraline (200 mg) over placebo on the CY-BOCS as early as week 3.”
BackgroundClomipramine Treatment of Childhood Obsessive-Compulsive Disorder: A Double-blind Controlled Study
Flament, M. F. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790330057007 · Cited by 466
(2013) · Acta Neurologica Belgica · doi:10.1007/13760.2240-2993 · Cited by 462
A Review of the Efficacy of Selective Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder
Pigott, T. A., & Seay, S. M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0206 · Cited by 454 · cited 1×
“However, problems in controlling for between-study differences, such as dose, duration, blinding, method of assessment and population changes, indicate that the results must be viewed cautiously (Pigott and Seay, 1999).”
BackgroundClomipramine and Exposure for Obsessive-Compulsive Rituals: 1
Marks, I. M., Stern, R. S., Mawson, D., Cobb, J., & McDonald, R. (1980) · British Journal of Psychiatry · doi:10.1192/bjp.136.1.1 · Cited by 448
Which SSRI? A Meta-Analysis of Pharmacotherapy Trials in Pediatric Obsessive-Compulsive Disorder
Geller, D. A., Biederman, J., Stewart, S. E., Mullin, B., Martin, A., Spencer, T., & Faraone, S. V. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.11.1919 · Cited by 434 · cited 2×
“Clearer advantages for staying on active treatment were shown in paroxetine-discontinuation studies in adults (Geller et al., 2003b; Hollander et al., 2003a) and in children and adolescents (Yaryura-Tobias et al., 1976).”
BackgroundRIDDLE, M. A., REEVE, E. A., YARYURA-TOBIAS, J. A., YANG, H. M., CLAGHORN, J. L., GAFFNEY, G., GREIST, J. H., HOLLAND, D., MCCONVILLE, B. J., PIGOTT, T., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00017 · Cited by 402 · cited 1×
“Riddle et al. (2001) examined fluvoxamine (50–200 mg) in 120 children aged 8–17 years.”
BackgroundClomipramine in the Treatment of Patients With Obsessive-Compulsive Disorder
(1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810320054008 · Cited by 388
D-Cycloserine Augmented Exposure Therapy for Obsessive-Compulsive Disorder
Kushner, M. G., Kim, S. W., Donahue, C., Thuras, P., Adson, D., Kotlyar, M., McCabe, J., Peterson, J., & Foa, E. B. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.020 · Cited by 384 · cited 1×
“Three small studies (Kushner et al., 2007; Storch et al., 2008; Wilhelm et al., 2008) each used different doses (100 mg, 125 mg and 250 mg) and different timings (1 h, 2 h and 4 h before ERP).”
BackgroundGarcia, A. M., Sapyta, J. J., Moore, P. S., Freeman, J. B., Franklin, M. E., March, J. S., & Foa, E. B. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.06.013 · Cited by 378 · cited 1×
“Additionally, in a reanalysis of the POTS data (Garcia et al., 2010), CBT was found to be less effective in ‘familial’ OCD, suggesting an influence of the clinical subtype.”
MethodAugmentation of Behavior Therapy With d -Cycloserine for Obsessive-Compulsive Disorder
Wilhelm, S., Buhlmann, U., Tolin, D. F., Meunier, S. A., Pearlson, G. D., Reese, H. E., Cannistraro, P., Jenike, M. A., & Rauch, S. L. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07050776 · Cited by 358 · cited 2×
“Three small studies (Kushner et al., 2007; Storch et al., 2008; Wilhelm et al., 2008) each used different doses (100 mg, 125 mg and 250 mg) and different timings (1 h, 2 h and 4 h before ERP).”
BackgroundResultDEVEAUGH-GEISS, J., MOROZ, G., BIEDERMAN, J., CANTWELL, D., FONTAINE, R., GREIST, J. H., REICHLER, R., KATZ, R., & LANDAU, P. (1992) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199201000-00008 · Cited by 349
RIDDLE, M. A., SCAHILL, L., KING, R. A., HARDIN, M. T., ANDERSON, G. M., ORT, S. I., SMITH, J. C., LECKMAN, J. F., & COHEN, D. J. (1992) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199211000-00011 · Cited by 345 · cited 1×
“Fixed 20 mg doses of fluoxetine were used in a 20-week cross-over study on 14 children that was arguably underpowered (Riddle et al., 1992).”
MethodObsessive-compulsive disorder and serotonin: Is there a connection?
Insel, T. R., Mueller, E. A., Alterman, I., Linnoila, M., & Murphy, D. L. (1985) · Biological Psychiatry · doi:10.1016/0006-3223(85)90176-3 · Cited by 343 · cited 1×
“The poor performance of the noradrenergic desipramine, relative to clomipramine, was demonstrated in a placebo-controlled cross-over study (Insel et al., 1985) and in two cross-over studies in children (Leonard et al., 1988, 1991).”
BackgroundObsessive-Compulsive Disorder: A Double-blind Trial of Clomipramine and Clorgyline
Insel, T. R. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.04390010015002 · Cited by 343 · cited 1×
“Similarly, superiority for clomipramine was demonstrated in head-to-head comparisons with imipramine (Foa et al., 1987; Volavka et al., 1985), nortryptline (Thoren et al., 1980) and clorgylline (Insel et al., 1983).”
BackgroundSoomro, G. M., Altman, D. G., Rajagopal, S., & Oakley Browne, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001765.pub3 · Cited by 342 · cited 1×
“A meta-analysis of SSRI versus placebo that included 17 selected studies (3097 participants), unequivocally demonstrated the efficacy of SSRIs in OCD (Soomro et al., 2008).”
ResultEvidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Self-citationGELLER, D. A., HOOG, S. L., HEILIGENSTEIN, J. H., RICARDI, R. K., TAMURA, R., KLUSZYNSKI, S., JACOBSON, J. G., & FLUOXETINE PEDIATRIC OCD STUDY TEAM (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200107000-00011 · Cited by 320 · cited 1×
“Geller et al. (2001) examined a larger cohort of children (n = 103; age 7–17 years), titrating fluoxetine doses upwards from 10 mg to 60 mg/day over 13 weeks, depending on clinical response.”
BackgroundMeta-analysis of the dose-response relationship of SSRI in obsessive–compulsive disorder
Bloch, M. H., McGuire, J., Landeros-Weisenberger, A., Leckman, J. F., & Pittenger, C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.50 · Cited by 317 · cited 1×
“A meta-analysis of nine SSRI studies was conducted to determine dose-related differences in efficacy and tolerability using a fixed effects model (Bloch et al., 2010).”
MethodRiluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314 · cited 1×
“Riluzole, another glutamate-modulating agent, was used as an adjunctive agent in a small (n = 13) open-label trial (Coric et al., 2005).”
MethodTollefson, G. D. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950070051010 · Cited by 314 · cited 3×
“Similar results were reported for fluoxetine, with the greatest benefit observed with the 60 mg dose (Montgomery et al., 1993; Tollefson et al., 1994), which was additionally significantly more effective than the 20 mg dose in a metaanalysis (Wood et al.”
BackgroundResultGoodman, W. K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810180077011 · Cited by 311
Meta‐analysis of randomized, controlled treatment trials for pediatric obsessive‐compulsive disorder
Watson, H. J., & Rees, C. S. (2008) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2007.01875.x · Cited by 306 · cited 1×
“Ten compared pharmacotherapy and three compared cognitive behaviour therapy (CBT) with controls (Watson and Rees, 2008).”
BackgroundHudak, R., & Gannon, J. M. (2022) · Current Clinical Practice · doi:10.1007/978-3-030-98709-1_5 · Cited by 306
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.12.1521 · Cited by 301 · cited 4×
“In contrast, studies with fluoxetine (Koran et al., 2002) and sertraline (Pato et al., 1988) that may have been underpowered did not differentiate between continuation treatment on active drug or placebo, though patients remaining on higher (60 mg) fluoxetine doses showed significantly lower…”
BackgroundResultInfluentialEfficacy of Drug Treatment in Obsessive–Compulsive Disorder: a Meta-Analytic Review
Piccinelli, M., Pini, S., Bellantuono, C., & Wilkinson, G. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.166.4.424 · Cited by 282 · cited 1×
“Early meta-analyses (Greist et al., 1995c; Jenike et al., 1990; Piccinelli et al.1995; Stein et al., 1995) showed that clomipramine and SSRIs are more effective than placebo and that clomipramine was associated with a significantly greater mean change in Y-BOCS scores, as well as a larger premature…”
BackgroundObsessive-compulsive severity spectrum in the community: prevalence, comorbidity, and course
Angst, J., Gamma, A., Endrass, J., Goodwin, R., Ajdacic, V., Eich, D., & R�ssler, W. (2004) · European Archives of Psychiatry and Clinical Neurosciences · doi:10.1007/s00406-004-0459-4 · Cited by 279 · cited 1×
“However, naturalistic follow-up studies (Angst et al., 2004; Reddy et al., 2010) that report recovery rates between 76% and 86% suggest that the frequency of resistance in ‘non-clinical’ samples may be lower than expected.”
BackgroundBehavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis
Kobak, K. A., Greist, J. H., Jefferson, J. W., Katzelnick, D. J., & Henk, H. J. (1998) · Psychopharmacology · doi:10.1007/s002130050558 · Cited by 276 · cited 1×
“Subsequent metaanalyses comparing RCTs of SRI and psychological interventions (Abramowitz, 1997; Kobak et al., 1998) also reported an apparent superiority in efficacy for clomipramine over SSRIs, other than fluoxetine or fluvoxamine, even when certain potentially confounding variables were…”
BackgroundParoxetine versus Clomipramine in the Treatment of Obsessive–Compulsive Disorder
Zohar, J., Judge, R., & Ocd Paroxetine Study Investigators (1996) · British Journal of Psychiatry · doi:10.1192/bjp.169.4.468 · Cited by 272 · cited 2×
“Zohar and Judge (1996) compared paroxetine and clomipramine, and at weeks 6, 8 and 12 showed similar placebo-referenced efficacy on OCD symptom scores, though paroxetine was superior to placebo on depression ratings whereas clomipramine was not.”
BackgroundNeuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.5.652 · Cited by 271 · cited 1×
“McDougle et al. (1990) reported benefit from adding openlabel pimozide (6.5 mg) in 17 patients unresponsive to fluvoxamine.”
BackgroundInfluentialClomipramine, self-exposure and therapist-aided exposure for obsessive–compulsive rituals
Marks, I. M., Lelliott, P., Basoglu, M., Noshirvani, H., Monteiro, W., Cohen, D., & Kasvikis, Y. (1988) · British Journal of Psychiatry · doi:10.1192/bjp.152.4.522 · Cited by 255
Denys, D., de Geus, F., van Megen, H. J. G. M., & Westenberg, H. G. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0803 · Cited by 248 · cited 1×
“However, another double-blind, placebo-controlled study (Denys et al., 2004) showed clear evidence of efficacy for quetiapine (< 300 mg) augmentation in 20 SRI-refractory patients, producing a mean decrease of 31% on baseline Y-BOCS, compared to those on adjunctive placebo who showed only 6% improvement.”
MethodNinan, P. T., Koran, L. M., Kiev, A., Davidson, J. R. T., Rasmussen, S. A., Zajecka, J. M., Robinson, D. G., Crits-Christoph, P., Mandel, F. S., & Austin, C. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0103 · Cited by 245 · cited 1×
“Ninan et al. (2006) evaluated the efficacy and safety of high-dose (400 mg) sertraline in OCD patients who had failed to respond to 16 weeks of standard dose (200 mg) sertraline.”
BackgroundClomipramine in obsessive-compulsive disorder
Katz, R. J., DeVeaugh-Geiss, J., & Landau, P. (1990) · Biological Psychiatry · doi:10.1016/0006-3223(90)90408-t · Cited by 245
Greist, J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950160039008 · Cited by 243 · cited 2×
“The dose–response relationship is less clear-cut for sertraline and citalopram (Greist et al., 1995a; Montgomery et al., 2001; Ushijima et al., 1997).”
BackgroundLeonard, H. L. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810340054007 · Cited by 229 · cited 1×
“The poor performance of the noradrenergic desipramine, relative to clomipramine, was demonstrated in a placebo-controlled cross-over study (Insel et al., 1985) and in two cross-over studies in children (Leonard et al., 1988, 1991).”
BackgroundPigott, T. A. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220042005 · Cited by 221
Bystritsky, A., Ackerman, D. L., Rosen, R. M., Vapnik, T., Gorbis, E., Maidment, K. M., & Saxena, S. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0418 · Cited by 220 · cited 1×
“A 6-week, double-blind, placebo-controlled study (Bystritsky et al., 2004) of adjunctive olanzapine was conducted in 26 OCD patients who had failed to respond to SRI monotherapy.”
BackgroundEvidence-based pharmacotherapy of obsessive–compulsive disorder
Fineberg, N. A., & Gale, T. M. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004675 · Cited by 211 · cited 4×
“No positive randomised controlled studies of antipsychotic monotherapy in OCD meet today’s standards, and OCD is not recognised as responding to these drugs on their own (Fineberg and Gale, 2005).”
BackgroundInfluentialSelf-citationA Controlled Study of Fluvoxamine and Exposure in Obsessive-Compulsive Disorder
COTTRAUX, J., MOLLARD, E., BOUVARD, M., MARKS, I., SLUYS, M., NURY, A. M., DOUGE, R., & CIALDELLA, P. (1990) · International Clinical Psychopharmacology · doi:10.1097/00004850-199001000-00002 · Cited by 203 · cited 1×
“Treatment responders, on uncontrolled SRI, from acutephase studies, have been followed for up to 2 years without tolerance developing (Cottraux et al., 1990; Katz et al., 1990; Rasmussen et al., 1997; Rosenbaum et al., 1998; Tollefson et al., 1994; Wagner et al., 1999).”
BackgroundD-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder
Storch, E. A., Merlo, L. J., Bengtson, M., Murphy, T. K., Lewis, M. H., Yang, M. C., Jacob, M. L., Larson, M., Hirsh, A., Fernandez, M., et al. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32819f8480 · Cited by 200
Hollander, E., Rossi, N. B., Sood, E., & Pallanti, S. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003730 · Cited by 197
Grant, P., Lougee, L., Hirschtritt, M., & Swedo, S. E. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0021 · Cited by 197 · cited 1×
“Two further small open-label studies of riluzole in children with OCD also reported improvement on the Y-BOCS without major adverse effects (Grant et al., 2007; Pittenger et al., 2008).”
BackgroundStorch, E. A., Murphy, T. K., Goodman, W. K., Geffken, G. R., Lewin, A. B., Henin, A., Micco, J. A., Sprich, S., Wilhelm, S., Bengtson, M., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.07.015 · Cited by 193
Fluoxetine in Children and Adolescents With OCD: A Placebo-Controlled Trial
LIEBOWITZ, M. R., TURNER, S. M., PIACENTINI, J., BEIDEL, D. C., CLARVIT, S. R., DAVIES, S. O., GRAAE, F., JAFFER, M., LIN, S.-H., SALLEE, F. R., et al. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200212000-00014 · Cited by 188 · cited 1×
“In a placebo-controlled trial spanning 7 years, Liebowitz et al. (2002) extended the dose range to 80 mg/ day for 2 weeks after an initial 6 weeks dosed up to 60 mg/ day.”
MethodGeller, D. A., Biederman, J., Stewart, S. E., Mullin, B., Farrell, C., Wagner, K. D., Emslie, G., & Carpenter, D. (2003) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454603322126313 · Cited by 187 · cited 2×
“Clearer advantages for staying on active treatment were shown in paroxetine-discontinuation studies in adults (Geller et al., 2003b; Hollander et al., 2003a) and in children and adolescents (Yaryura-Tobias et al., 1976).”
BackgroundMontgomery, S. A., Kasper, S., Stein, D. J., Hedegaard, K. B., & Lemming, O. M. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200103000-00002 · Cited by 187 · cited 1×
“The dose–response relationship is less clear-cut for sertraline and citalopram (Greist et al., 1995a; Montgomery et al., 2001; Ushijima et al., 1997).”
BackgroundRiluzole in the Treatment of Mood and Anxiety Disorders
Pittenger, C., Coric, V., Banasr, M., Bloch, M., Krystal, J. H., & Sanacora, G. (2008) · CNS Drugs · doi:10.2165/00023210-200822090-00004 · Cited by 177 · cited 1×
“Two further small open-label studies of riluzole in children with OCD also reported improvement on the Y-BOCS without major adverse effects (Grant et al., 2007; Pittenger et al., 2008).”
BackgroundMontgomery, S. (1993) · European Neuropsychopharmacology · doi:10.1016/0924-977x(93)90266-o · Cited by 172 · cited 1×
“Similar results were reported for fluoxetine, with the greatest benefit observed with the 60 mg dose (Montgomery et al., 1993; Tollefson et al., 1994), which was additionally significantly more effective than the 20 mg dose in a metaanalysis (Wood et al., 1993).”
Result(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.9.1209 · Cited by 164 · cited 1×
“Early meta-analyses (Greist et al., 1995c; Jenike et al., 1990; Piccinelli et al.1995; Stein et al., 1995) showed that clomipramine and SSRIs are more effective than placebo and that clomipramine was associated with a significantly greater mean change in Y-BOCS scores, as well as a larger premature…”
BackgroundMcDougle, C. J., Price, L. H., Goodman, W. K., Charney, D. S., & Heninger, G. R. (1991) · PubMed · Cited by 161
Minchin, M. (1987) · Neurochemistry International · doi:10.1016/0197-0186(87)90040-4 · Cited by 159
A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder
Stewart, S. E., Jenike, E. A., Hezel, D. M., Stack, D. E., Dodman, N. H., Shuster, L., & Jenike, M. A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c856de · Cited by 158
Hollander, E., Allen, A., Steiner, M., Wheadon, D. E., Oakes, R., Burnham, D. B., & Paroxetine OCD Study Group (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0919 · Cited by 156
Placebo-controlled trial of fluoxetine and phenelzine for obsessive- compulsive disorder
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.9.1261 · Cited by 155 · cited 2×
“Jenike et al. (1997) demonstrated a significant advantage for fluoxetine over phenelzine, which did not distinguish from placebo, suggesting lack of efficacy for MAOIs in OCD.”
BackgroundShapira, N. A., Ward, H. E., MANDOKI, M. W., Murphy, T. K., Yang, M. C. K., Blier, P., & Goodman, W. K. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.11.010 · Cited by 154
A Double Blind Comparison of Venlafaxine and Paroxetine in Obsessive-Compulsive Disorder
Denys, D., van der Wee, N., van Megen, H. J. G. M., & Westenberg, H. G. M. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000095342.32154.54 · Cited by 151 · cited 1×
“Venlafaxine was also compared to paroxetine in a non-placebo, double-blind study of non-depressed OCD cases (Denys et al., 2003).”
ResultDouble-blind comparative study of clomipramine and amitriptyline in obsessive neurosis
Ananth, J., Pecknold, J. C., Steen, N. V. D., & Engelsmann, F. F. (1981) · Progress in Neuro-Psychopharmacology · doi:10.1016/0364-7722(81)90077-1 · Cited by 150 · cited 1×
“A significant within-group advantage emerged for clomipramine but not amitriptyline in a small study (Ananth et al., 1981).”
BackgroundWCA Recommendations for the Long-Term Treatment of Obsessive-Compulsive Disorder in Adults
Greist, J. H., Bandelow, B., Hollander, E., Marazziti, D., Montgomery, S. A., Nutt, D. J., Okasha, A., Swinson, R. P., & Zohar, J. (2003) · CNS Spectrums · doi:10.1017/s1092852900006908 · Cited by 143 · cited 1×
“Recent guidelines (Greist et al., 2003; Koran et al., 2007) recommend continuation of pharmacotherapy for a minimum of 1–2 years in treatment-responsive individuals and emphasise the importance of long-term treatment from the outset.”
BackgroundEfficacy of Sertraline in the Long-Term Treatment of Obsessive-Compulsive Disorder
Koran, L. M., Hackett, E., Rubin, A., Wolkow, R., & Robinson, D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.88 · Cited by 140 · cited 2×
“In contrast, studies with fluoxetine (Koran et al., 2002) and sertraline (Pato et al., 1988) that may have been underpowered did not differentiate between continuation treatment on active drug or placebo, though patients remaining on higher (60 mg) fluoxetine doses showed significantly lower…”
BackgroundResultMeta-analysis of pharmacotherapy trials for obsessive-compulsive disorder
Stein, D. J., Spadaccini, E., & Hollander, E. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199503000-00002 · Cited by 138 · cited 1×
“Early meta-analyses (Greist et al., 1995c; Jenike et al., 1990; Piccinelli et al.1995; Stein et al., 1995) showed that clomipramine and SSRIs are more effective than placebo and that clomipramine was associated with a significantly greater mean change in Y-BOCS scores, as well as a larger premature…”
BackgroundMemantine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: An Open-Label Trial
Aboujaoude, E., Barry, J. J., & Gamel, N. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318192e9a4 · Cited by 136 · cited 1×
“In a 12-week, open-label trial (Aboujaoude et al., 2009), adjunctive memantine (5–20 mg) was prescribed to 15 patients who had failed to respond adequately to 12 weeks of SRI.”
MethodSkapinakis, P., Papatheodorou, T., & Mavreas, V. G. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.07.002 · Cited by 136 · cited 1×
“A meta-analyses (Skapinakis et al., 2007) concluded that patients randomised to the antipsychotic arm of trials were more likely (up to three times) to respond than placebo.”
MethodThe Use of Aripiprazole in Obsessive-Compulsive Disorder: Preliminary Observations in 8 Patients
Connor, K. M., Payne, V. M., Gadde, K. M., Zhang, W., & Davidson, J. R. T. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0107 · Cited by 135 · cited 1×
“%) cases, each showing at least 37.5% reduction in Y-BOCS score (Connor et al., 2005).”
BackgroundInfluentialStein, D. J., Wreford Andersen, E., Tonnoir, B., & Fineberg, N. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x178838 · Cited by 134 · cited 5×
“…Disability Scale (SDS); and Short Form (SF-36), respectively, in two prospective, randomised, placebo-controlled trials of escitalopram (Fineberg et al., 2007b; Stein et al., 2007), suggest that SSRI is associated with clinically relevant improvements in HR-QoL in OCD (Hollander et al., 2010).”
BackgroundMethodInfluentialSelf-citationMcDOUGLE, C. J., PRICE, L. H., GOODMAN, W. K., CHARNEY, D. S., & HENINGER, G. R. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199106000-00005 · Cited by 134 · cited 1×
“These include adjunctive lithium carbonate (McDougle et al., 1991; Pigott et al., 1991), buspirone (Grady et al.”
BackgroundGreist, J. H., Jefferson, J. W., Kobak, K. A., Chouinard, G., DuBoff, E., Halaris, A., Kim, S. W., Koran, L., Liebowtiz, M. R., Lydiard, B., et al. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199506000-00001 · Cited by 133 · cited 2×
“The dose–response relationship is less clear-cut for sertraline and citalopram (Greist et al., 1995a; Montgomery et al., 2001; Ushijima et al., 1997).”
BackgroundCarey, P. D., Vythilingum, B., Seedat, S., Muller, J. E., van Ameringen, M., & Stein, D. J. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-5 · Cited by 133
Berlin, H. A., Koran, L. M., Jenike, M. A., Shapira, N. A., Chaplin, W., Pallanti, S., & Hollander, E. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05266gre · Cited by 131
Clomipramine, Clonazepam, and Clonidine Treatment of Obsessive-Compulsive Disorder
HEWLETT, W. A., VINOGRADOV, S., & AGRAS, W. S. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199212000-00008 · Cited by 129 · cited 1×
“Clonazepam, a benzodiazepine with putative effects on serotonin neurotransmission, may be beneficial (Hewlett et al., 1992; Pigott et al., 1992b), possibly through assisting with associated anxiety, though has little impact on the core symptoms of OCD (Hollander et al.”
Background(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.4.647 · Cited by 127 · cited 1×
“, 1991), buspirone (Grady et al., 1993; McDougle et al., 1993; Pigott et al., 1992a), pindolol (Blier and Bergeron, 1996; Dannon et al.”
BackgroundHoehn-Saric, R., Ninan, P., Black, D. W., Stahl, S., Greist, J. H., Lydiard, B., McElroy, S., Zajecka, J., Chapman, D., Clary, C., et al. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.76 · Cited by 126 · cited 1×
“Studies showed desipramine as inferior compared to SSRIs such as fluvoxamine (Goodman et al., 1990) and sertraline (Hoehn-Saric et al., 2000).”
BackgroundFreeman, C. P. L., Trimble, M., Deakin, J. F. W., Stokes, T., & Ashford, J. J. (1994) · PubMed · Cited by 125
Clomipramine and imipramine in obsessive-compulsive disorder
Volavka, J., Neziroglu, F. A., & Yaryura-Tobias, J. A. (1985) · Psychiatry Research · doi:10.1016/0165-1781(85)90092-7 · Cited by 124 · cited 2×
“Similarly, superiority for clomipramine was demonstrated in head-to-head comparisons with imipramine (Foa et al., 1987; Volavka et al., 1985), nortryptline (Thoren et al.”
BackgroundVan Ameringen, M., Mancini, C., Patterson, B., & Bennett, M. (2006) · Depression and Anxiety · doi:10.1002/da.20118 · Cited by 124
Muscatello, M. R. A., Bruno, A., Pandolfo, G., Micò, U., Scimeca, G., Romeo, V. M., Santoro, V., Settineri, S., Spina, E., & Zoccali, R. A. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31820e3db6 · Cited by 122
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.5.819 · Cited by 120
Goodman, W. K., Kozak, M. J., Liebowitz, M., & White, K. L. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199603000-00003 · Cited by 120
Pallanti, S., Quercioli, L., & Bruscoli, M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1015 · Cited by 118
Dannon, P. N., Sasson, Y., Hirschmann, S., Iancu, I., Grunhaus, L. J., & Zohar, J. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)00065-1 · Cited by 116 · cited 1×
“, 1992a), pindolol (Blier and Bergeron, 1996; Dannon et al., 2000; Mundo et al., 1998), desipramine (Barr et al.”
Lack of efficacy of clozapine monotherapy in refractory obsessive- compulsive disorder
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.12.1812 · Cited by 116 · cited 1×
“In a 6-week trial of open-label clozapine monotherapy in 12 highly treatment-refractory OCD subjects, no significant change was noted in the baseline measures in any of the 10 patients who completed the study (McDougle et al., 1995).”
BackgroundPIGOTT, T. A., PATO, M. T., L??HEUREUX, F., HILL, J. L., GROVER, G. N., BERNSTEIN, S. E., & MURPHY, D. L. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199108000-00004 · Cited by 115
Hollander, E., Stein, D. J., Fineberg, N. A., Marteau, F., & Legault, M. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05911blu · Cited by 115 · cited 3×
“Individuals with OCD report substantial impairment in health-related quality of life (HR-QoL) and social functioning (Hollander et al., 2010), and children with early onset OCD are particularly badly affected (Piacentini and Langley, 2004).”
BackgroundSelf-citation(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.5.572 · Cited by 115
PIGOTT, T. A., LʼHEUREUX, F., HILL, J. L., BIHARI, K., BERNSTEIN, S. E., & MURPHY, D. L. (1992) · Current Opinion in Cardiology · doi:10.1097/00001573-199202000-00003 · Cited by 113
Fallon, B. A., Liebowitz, M. R., Campeas, R., Schneier, F. R., Marshall, R., Davies, S., Goetz, D., & Klein, D. F. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.10.918 · Cited by 111 · cited 1×
“Intravenous clomipramine was noted to be more effective than placebo in a double-blind study investigating refractory OCD (Fallon et al., 1998).”
BackgroundLi, X., May, R. S., Tolbert, L. C., Jackson, W. T., Flournoy, J. M., & Baxter, L. R. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0610 · Cited by 110 · cited 1×
“In an 8-week, double-blind, placebo-controlled study (Li et al., 2005), adjunctive risperidone (1 mg) and haloperidol (2 mg) were each significantly superior to placebo in reducing obsessions and anxiety in 16 SRI-resistant OCD patients.”
BackgroundMatsunaga, H., Nagata, T., Hayashida, K., Ohya, K., Kiriike, N., & Stein, D. J. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04369 · Cited by 110
Fluvoxamine Versus Clomipramine for Obsessive-Compulsive Disorder: A Double-Blind Comparison
Koran, L. M., McElroy, S. L., Davidson, J. R. T., Rasmussen, S. A., Hollander, E., & Jenike, M. A. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199604000-00004 · Cited by 106
Fineberg, N. A., Sivakumaran, T., Roberts, A., & Gale, T. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200507000-00005 · Cited by 105
Self-citationTreatment of Obsessive Compulsive Disorder with Clomipramine
DeVeaugh-Geiss, J., Landau, P., & Katz, R. J. (1989) · Psychiatric Annals · doi:10.3928/0048-5713-19890201-11 · Cited by 103
Fineberg, N. A., Stein, D. J., Premkumar, P., Carey, P., Sivakumaran, T., Vythilingum, B., Seedat, S., Westenberg, H., & Denys, D. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000215083.57801.11 · Cited by 103 · cited 1×
“A meta-analysis (Fineberg et al., 2006) of three qualifying double-blind, randomised, placebo-controlled quetiapine trials showed evidence of efficacy for quetiapine (< 400 mg/day) on the primary efficacy criterion (changes Table 5.”
BackgroundSelf-citationHollander, E., Koran, L. M., Goodman, W. K., Greist, J. H., Ninan, P. T., Yang, H., Li, D., & Barbato, L. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0604 · Cited by 103
Rapid benefit of intravenous pulse loading of clomipramine in obsessive- compulsive disorder
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.3.396 · Cited by 102 · cited 1×
“Similarly, Koran et al. (1997) demonstrated that pulseloading with intravenous clomipramine produced a large and rapid decrease in obsessive symptoms (but oral pulse loading did not), though the early advantages disappeared later.”
BackgroundMaina, G., Pessina, E., Albert, U., & Bogetto, F. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.01.001 · Cited by 101 · cited 1×
“An 8-week, single-blind, randomised, non-placebo trial (Maina et al., 2008) compared adjunctive risperidone (1–3 mg) with olanzapine (2.”
BackgroundMemantine augmentation for refractory obsessive–compulsive disorder
Pasquini, M., & Biondi, M. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.04.013 · Cited by 100 · cited 1×
“Preliminary findings (Pasquini and Biondi, 2006) reporting an immediate beneficial effect of augmentation with the glutamatergic compound memantine, in one of two cases, triggered the investigation of memantine in a number of small uncontrolled studies.”
BackgroundRomano, S., Goodman, W., Tamura, R., & Gonzales, J. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200102000-00009 · Cited by 98 · cited 3×
“Not all studies are designed to differentiate between the gradual re-emergence of OCD and early ‘discontinuation effects’ occurring soon after drug termination, which are related to the pharmacological properties of the compound, and that are believed to complicate clomipramine and paroxetine more than fluoxetine (Rom…”
BackgroundResultInfluentialFux, M., Benjamin, J., & Belmaker, R. H. (1999) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145799001546 · Cited by 97
A double-blind, placebo-controlled trial of clonazepam in obsessive–compulsive disorder
Hollander, E., Kaplan, A., & Stahl, S. M. (2003) · The World Journal of Biological Psychiatry · doi:10.3109/15622970309167908 · Cited by 97
Escitalopram prevents relapse of obsessive-compulsive disorder
Fineberg, N. A., Tonnoir, B., Lemming, O. M., & Stein, D. J. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.11.005 · Cited by 95 · cited 4×
“…the Sheehan Disability Scale (SDS); and Short Form (SF-36), respectively, in two prospective, randomised, placebo-controlled trials of escitalopram (Fineberg et al., 2007b; Stein et al., 2007), suggest that SSRI is associated with clinically relevant improvements in HR-QoL in OCD (Hollander et…”
BackgroundInfluentialSelf-citationLeonard, H., Swedo, S. E., Rapoport, J. L., Coffey, M., & Cheslow, D. L. (1988) · PubMed · Cited by 94
Albert, U., Aguglia, E., Maina, G., & Bogetto, F. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1108 · Cited by 93 · cited 1×
“However, venlafaxine compared unfavourably with clomipramine in a smaller singleblind study, which failed to reach significance, in which 42.6% (20/47) of the clomipramine group were responders compared to 34.6% (9/26) on venlafaxine (Albert et al., 2002).”
ResultInfluentialKoran, L. M., Gamel, N. N., Choung, H. W., Smith, E. H., & Aboujaoude, E. N. (2005) · PubMed · Cited by 91
Bisserbe, J., Lane, R., Flament, M., & France-Belgian OCD Study Group (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)89646-0 · Cited by 91 · cited 2×
“While some individual trials were small and therefore subject to type II error, the study by Bisserbe et al. (1997) was sufficiently powered and demonstrated a significant advantage for sertraline over clomipramine; however, the advantage, apparent for certain efficacy measures in the…”
BackgroundResultMundo, E., Bianchi, L., & Bellodi, L. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00005 · Cited by 87
Placebo-Controlled, Multicenter Study of Sertraline Treatment for Obsessive-Compulsive Disorder
Kronig, M. H., Apter, J., Asnis, G., Bystritsky, A., Curtis, G., Ferguson, J., Landbloom, R., Munjack, D., Riesenberg, R., Robinson, D., et al. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199904000-00013 · Cited by 84
Grant, P., Song, J. Y., & Swedo, S. E. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0009 · Cited by 84 · cited 1×
“These findings were supported by preliminary results of an ongoing trial (Grant et al., 2010), despite the occurrence of two cases of pancreatitis.”
ResultLópez-Ibor, J. J., Saíz, J., Cottraux, J. A., Note, I. D., Viñas, R., Bourgeois, M., Hernández, M., & Gómez-Pérez, J. C. (1996) · European Neuropsychopharmacology · doi:10.1016/0924-977x(95)00071-v · Cited by 83 · cited 1×
“In contrast, another small study by Lopez-Ibor et al. (1996) detected an advantage for clomipramine over fluoxetine (40 mg) on secondary but not primary outcome measures.”
ResultTranslational approaches to obsessive‐compulsive disorder: from animal models to clinical treatment
Fineberg, N., Chamberlain, Sr., Hollander, E., Boulougouris, V, & Robbins, T. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01422.x · Cited by 82
Self-citationKoran, L. M., Gamel, N. N., Choung, H. W., Smith, E. H., & Aboujaoude, E. N. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0415 · Cited by 82 · cited 1×
“Thirty patients (15 treatment-naïve and 15 treatment-experienced) were enrolled into a 12-week open-label mirtazapine (30–60 mg) trial (Koran et al., 2005).”
MethodAdjunctive glycine in the treatment of obsessive-compulsive disorder in adults
Greenberg, W. M., Benedict, M. M., Doerfer, J., Perrin, M., Panek, L., Cleveland, W. L., & Javitt, D. C. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.10.007 · Cited by 80 · cited 1×
“Glycine, another NMDA receptor modulator, was investigated in a 12-week randomised, double-blind, placebo-controlled trial (up to 60 mg) (Greenberg et al., 2009).”
BackgroundPIGOTT, T. A., L??HEUREUX, F., HILL, J. L., BIHARI, K., BERNSTEIN, S. E., & MURPHY, D. L. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199202000-00003 · Cited by 80
(1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.10.1328 · Cited by 79
Soltani, F., Sayyah, M., Feizy, F., Malayeri, A., Siahpoosh, A., & Motlagh, I. (2010) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1145 · Cited by 78 · cited 1×
“Australian & New Zealand Journal of Psychiatry, 47(2) ondansetron was explored in an 8-week, double-blind, placebo-controlled pilot study (n = 42) (Soltani et al., 2010) in which patients were randomised to receive either fluoxetine (20 mg/day) and ondansetron (4 mg/day) or fluoxetine (20 mg/day) and placebo.”
BackgroundKordon, A., Wahl, K., Koch, N., Zurowski, B., Anlauf, M., Vielhaber, K., Kahl, K. G., Broocks, A., Voderholzer, U., & Hohagen, F. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318185e735 · Cited by 78
Drummond, L. M. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.163.2.223 · Cited by 76
Vulink, N. C. C., Denys, D., Fluitman, S. B. A. H. A., Meinardi, J. C. M., & Westenberg, H. G. M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04269 · Cited by 75 · cited 1×
“Based upon positive results for adjunctive quetiapine in SRI-resistant OCD (see below), Vulink et al. (2009) performed a double-blind, randomized placebo-controlled study of quetiapine (300–450 mg/day) in combination with citalopram (60 mg/day) in 76 OCD patients who were treatment-naïve or…”
BackgroundPallanti, S., Bernardi, S., Antonini, S., Singh, N., & Hollander, E. (2009) · CNS Drugs · doi:10.2165/11530240-000000000-00000 · Cited by 74 · cited 1×
“In addition, an openlabel study of ondansetron (Pallanti et al., 2009) showed clinical response and good tolerability in treatment-resistant patients.”
BackgroundClozapine-Induced Obsessive-Compulsive Syndromes Improve in Combination With Aripiprazole
Englisch, S., Esslinger, C., Inta, D., Weinbrenner, A., Peus, V., Gutschalk, A., Schirmbeck, F., & Zink, M. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31819cc8e6 · Cited by 73 · cited 2×
“, 2003) or with the addition of aripiprazole (Englisch et al., 2009).”
BackgroundCognitive‐behavioral therapy for children who have obsessive‐compulsive disorder
Piacentini, J. C., & Langley, A. K. (2004) · Journal of Clinical Psychology · doi:10.1002/jclp.20082 · Cited by 73 · cited 2×
“Individuals with OCD report substantial impairment in health-related quality of life (HR-QoL) and social functioning (Hollander et al., 2010), and children with early onset OCD are particularly badly affected (Piacentini and Langley, 2004).”
BackgroundSumatriptan, 5-HT1D receptors and obsessive-compulsive disorder
Koran, L. M., Pallanti, S., & Quercioli, L. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00082-7 · Cited by 71
Pessina, E., Albert, U., Bogetto, F., & Maina, G. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832e9b91 · Cited by 71 · cited 1×
“A small open-label pilot study (Pessina et al., 2009) explored the efficacy of flexible doses of aripiprazole (< 20 mg) in 12 SRI-resistant patients.”
BackgroundReddy, Y. C. J., Alur, A. M., Manjunath, S., Kandavel, T., & Math, S. B. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181dbfb53 · Cited by 69 · cited 1×
“However, naturalistic follow-up studies (Angst et al., 2004; Reddy et al., 2010) that report recovery rates between 76% and 86% suggest that the frequency of resistance in ‘non-clinical’ samples may be lower than expected.”
BackgroundSzegedi, A., Wetzel, H., Leal, M., Härtter, S., & Hiemke, C. (1996) · PubMed · Cited by 67
de Sá, A. R., Hounie, A. G., Sampaio, A. S., Arrais, J., Miguel, E. C., & Elkis, H. (2009) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2008.11.005 · Cited by 67 · cited 2×
“This may be particularly evident for clozapine (Sa et al., 2009), though there have also been reports of obsessive symptoms in patients with schizophrenia improving with clozapine treatment (Kumar et al.”
BackgroundCitalopram for treatment-resistant obsessive-compulsive disorder
Pallanti, S., Quercioli, L., Paiva, R. S., & Koran, L. M. (1999) · European Psychiatry · doi:10.1016/s0924-9338(99)80725-1 · Cited by 66 · cited 1×
“In a randomised open-label trial (Pallanti et al., 1999), nine treatment-refractory patients were given citalopram with clomipramine and seven were treated with citalopram alone.”
BackgroundMundo, E., Rouillon, F., Figuera, M. L., & Stigler, M. (2001) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.317 · Cited by 66
A 2-year study of sertraline in the treatment of obsessive-compulsive disorder
Rasmussen, S., Hackett, E., DuBoff, E., Greist, J., Halaris, A., Koran, L. M., Liebowitz, M., Lydiard, R. B., McElroy, S., Mendels, J., et al. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199711000-00003 · Cited by 63 · cited 1×
“Treatment responders, on uncontrolled SRI, from acutephase studies, have been followed for up to 2 years without tolerance developing (Cottraux et al., 1990; Katz et al., 1990; Rasmussen et al., 1997; Rosenbaum et al., 1998; Tollefson et al., 1994; Wagner et al., 1999).”
BackgroundAntidepressant-Induced Sexual Dysfunction among Newer Antidepressants in a Naturalistic Setting
Lee, K.-U., Lee, Y. M., Nam, J.-M., Lee, H.-K., Kweon, Y.-S., Lee, C. T., & Jun, T.-Y. (2010) · Psychiatry Investigation · doi:10.4306/pi.2010.7.1.55 · Cited by 63 · cited 2×
“…and, if necessary, strategies such as dose reduction, short drug holidays or use of drugs with restorative potency, for example mirtazapine (Lee et al., 2010), sildenafil (Farre et al., 2004), agomelatine (Eser et al., 2010) and mianserin (Aizenberg et al., 1999), can be considered in…”
BackgroundBergeron, R., Ravindran, A. V., Chaput, Y., Goldner, E., Swinson, R., van Ameringen, M. A., Austin, C., & Hadrava, V. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200204000-00007 · Cited by 62 · cited 1×
“In addition, in the double-blind comparison of sertraline (n = 77) and fluoxetine (n = 73) (Bergeron et al., 2001), no significant difference was seen at the 24-week end point on any primary efficacy measure.”
BackgroundCitalopram Treatment of Compulsive Shopping: An Open-Label Study
Pallanti, S., Quercioli, L., & Koran, L. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0908 · Cited by 62
Naltrexone augmentation in OCD: A double-blind placebo-controlled cross-over study
Amiaz, R., Fostick, L., Gershon, A. A., & Zohar, J. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.01.006 · Cited by 61 · cited 1×
“, 2001) and naltrexone (Amiaz et al., 2008) were not effective and in some cases made OCD symptoms worse.”
BackgroundMaina, G., Albert, U., Ziero, S., & Bogetto, F. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200301000-00004 · Cited by 61 · cited 1×
“A small retrospective study (Maina et al., 2003) showed that the majority of patients (15 of 18; 83.”
BackgroundMundo, E., Guglielmo, E., & Bellodi, L. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199809000-00005 · Cited by 59
Greist, J. H., Jefferson, J. W., Rosenfeld, R., Gutzmann, L. D., March, J. S., & Barklage, N. E. (1990) · PubMed · Cited by 58
Tenney, N. H., Denys, D. A. J. P., van Megen, H. J. G. M., Glas, G., & Westenberg, H. G. M. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200301000-00005 · Cited by 58 · cited 1×
“Seventy-five individuals each received paroxetine (60 mg) and venlafaxine (300 mg), with both treatments appearing equally effective at reducing Y-BOCS scores as well as QoL measures (Tenney et al., 2003).”
BackgroundPsychosocial Function and Economic Costs of Obsessive-Compulsive Disorder
Hollander, E., Stein, D. J., Kwon, J. H., Rowland, C., Wong, C. M., Broatch, J., & Himelein, C. (1998) · CNS Spectrums · doi:10.1017/s1092852900007239 · Cited by 58
Blier, P., & Bergeron, R. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199603000-00005 · Cited by 57 · cited 1×
“, 1992a), pindolol (Blier and Bergeron, 1996; Dannon et al., 2000; Mundo et al., 1998), desipramine (Barr et al.”
Diniz, J., Shavitt, R., Pereira, C., Hounie, A., Pimentel, I., Koran, L., Dainesi, S., & Miguel, E. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108099423 · Cited by 57 · cited 2×
“In another study (Diniz et al., 2010), combining fluoxetine with clomipramine was less effective than fluoxetine monotherapy in SSRI nonresponders.”
BackgroundResultMarazziti, D., Pfanner, C., Dell’osso, B., Ciapparelli, A., Presta, S., Corretti, G., Di Nasso, E., Mungai, F., & Dell’osso, L. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105053299 · Cited by 56 · cited 1×
“A naturalistic study (Marazziti et al., 2005) assessed the long-term efficacy of adjunctive olanzapine (2.”
BackgroundVenlafaxine in Obsessive-compulsive Disorder
Yaryura-Tobias, J. A. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830070103016 · Cited by 53 · cited 1×
“A small, placebo-controlled trial (n = 30) failed to separate venlafaxine from placebo (Yaryura-Tobias and Neziroglu, 1996).”
BackgroundMilanfranchi, A., Ravagli, S., Lensi, P., Marazziti, D., & Cassano, G. B. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199705000-00002 · Cited by 52
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.9.1293 · Cited by 49
Uzun, Ö. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108098809 · Cited by 49
Sustained response versus relapse: the pharmacotherapeutic goal for obsessive–compulsive disorder
Fineberg, N. A., Pampaloni, I., Pallanti, S., Ipser, J., & Stein, D. J. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32825ea312 · Cited by 48 · cited 4×
“…the Sheehan Disability Scale (SDS); and Short Form (SF-36), respectively, in two prospective, randomised, placebo-controlled trials of escitalopram (Fineberg et al., 2007b; Stein et al., 2007), suggest that SSRI is associated with clinically relevant improvements in HR-QoL in OCD (Hollander et…”
BackgroundInfluentialSelf-citationPampaloni, I., Sivakumaran, T., Hawley, C., Al Allaq, A., Farrow, J., Nelson, S., & Fineberg, N. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109104850 · Cited by 47 · cited 1×
“Pampaloni et al. (2010) assessed long-term, high-dose SSRI prescribing in a specialist OCD outpatient service.”
BackgroundSelf-citationDenys, D. A. J. P., Fineberg, N. A., Carey, P. D., & Stein, D. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.12.014 · Cited by 44
Self-citationLong-Term Pharmacotherapy of Obsessive-Compulsive Disorder: A Double-Blind Controlled Study
Mundo, E., Bareggi, S. R., Pirola, R., Bellodi, L., & Smeraldi, E. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199702000-00002 · Cited by 44
Agomelatine: The evidence for its place in the treatment of depression
Eser, D. (2009) · Core Evidence · doi:10.2147/ce.s6005 · Cited by 37 · cited 2×
“, 2004), agomelatine (Eser et al., 2010) and mianserin (Aizenberg et al.”
BackgroundKim, S.-W., Shin, I.-S., Kim, J.-M., Youn, T., Yang, S.-J., Hwang, M. Y., & Yoon, J.-S. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318184fafd · Cited by 36 · cited 1×
“Some authors report treatmentemergent obsessions during the treatment of schizophrenia with second-generation antipsychotics (Kim et al., 2009).”
BackgroundPharmacotherapy of obsessive compulsive disorder-experience with fluoxetine
Wood, A., Tollefson, G. D., & Birkett, M. (1993) · International Clinical Psychopharmacology · doi:10.1097/00004850-199300840-00015 · Cited by 35 · cited 2×
“, 1994), which was additionally significantly more effective than the 20 mg dose in a metaanalysis (Wood et al., 1993).”
BackgroundResultAbsence of Cardiovascular Adverse Effects of Sertraline in Children and Adolescents
Wilens, T. E., Biederman, J., March, J. S., Wolkow, R., FINE, C. S., Millstein, R., Faraone, S. V., GELLER, D. A., & Spencer, T. J. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199905000-00019 · Cited by 34 · cited 1×
“Wilens et al. (1999) suggested that the adverse effects were not clinically meaningful and that sertraline is safe in children, in doses up to 200 mg.”
BackgroundDougherty, D. D., Jameson, M., Deckersbach, T., Loh, R., Thompson-Hollands, J., Jenike, M., & Keuthen, N. J. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32833119d8 · Cited by 32 · cited 1×
“Dougherty et al. (2009) randomly assigned 30 patients to 20 mg or 30 mg (high dose) escitalopram in an open-label design.”
MethodSpecific aspects of erectile dysfunction in psychiatry
Farré, J. M., Forà, F., & Mg, L. (2004) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901243 · Cited by 32 · cited 2×
“…and, if necessary, strategies such as dose reduction, short drug holidays or use of drugs with restorative potency, for example mirtazapine (Lee et al., 2010), sildenafil (Farre et al., 2004), agomelatine (Eser et al., 2010) and mianserin (Aizenberg et al., 1999), can be considered in stable cases.”
BackgroundNicotine augmentation for refractory obsessive-compulsive disorder. A case report
Pasquini, M., Garavini, A., & Biondi, M. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.08.011 · Cited by 31 · cited 1×
“An interesting case report in which nicotine (4 mg) added to clomipramine and valproate produced a clinical response may merit further attention (Pasquini et al., 2005).”
BackgroundFoa, E. B., Steketee, G. S., Kozak, M. J., & Dugger, D. (1987) · PubMed · Cited by 30
High doses of sertraline for treatment-resistant obsessive-compulsive disorder
Byerly, M., Goodman, W. K., & Christensen, R. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.9.1232b · Cited by 27 · cited 1×
“In contrast, results from uncontrolled case studies suggest that increasing SSRI doses beyond formulary limits is well tolerated and can improve outcomes (Bejerot and Bodlund, 1998; Byerly et al., 1996).”
ResultBogetto, F., Albert, U., & Maina, G. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00012-3 · Cited by 26 · cited 1×
“A significant difference in favour of rapid dose escalation was seen at weeks 4 and 6 of a single-blind study comparing dose escalation with sertraline to 150 mg over 5 days, with slower dose escalation over 15 days, but this advantage was not sustained (Bogetto et al., 2002).”
BackgroundResponse to high doses of citalopram in treatment‐resistant obsessive‐compulsive disorder
Bejerot, S., & Bodlund, O. (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb10108.x · Cited by 25 · cited 1×
“In contrast, results from uncontrolled case studies suggest that increasing SSRI doses beyond formulary limits is well tolerated and can improve outcomes (Bejerot and Bodlund, 1998; Byerly et al., 1996).”
ResultQuetiapine and Ziprasidone as Adjuncts in Treatment-Resistant Obsessive-Compulsive Disorder
SAVAS, H. A., Yumru, M., & Özen, M. E. (2008) · Clinical Drug Investigation · doi:10.2165/00044011-200828070-00005 · Cited by 22
Dunbar, G., Steiner, M. S., Bushnell, W. D., Gergel, I. P., & Wheadon, D. E. (1995) · European Neuropsychopharmacology · doi:10.1016/0924-977x(95)90660-6 · Cited by 22 · cited 1×
“The relatively high early relapse rates which were seen in the clomipramine studies were possibly confounded by discontinuation effects (Dunbar et al. 1995; Fineberg et al. 2007a; Leonard et al., 1988).”
BackgroundObsessive compulsive disorder: a practical guide.
Bejerot, S. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.02022.x · Cited by 21
Aizenberg, D., Naor, S., Zemishlany, Z., & Weizman, A. (1999) · PubMed · Cited by 20
Long Term Treatment of Obsessive-Compulsive Disorder
Ravizza, L., Maina, G., Bogetto, F., Albert, U., Barzega, G., & Bellino, S. (1998) · CNS Drugs · doi:10.2165/00023210-199810040-00003 · Cited by 19 · cited 2×
“(2007) suggested reducing by decrements of 10–25% every 1–2 months while observing for symptom return or exacerbation, in which case pharmacotherapy could be reinstated, though the same level of improvement cannot be guaranteed (Ravizza et al., 1998).”
BackgroundHarris, E., Eng, H. Y., Kowatch, R. A., Delgado, S. V., & Saldaña, S. N. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0126 · Cited by 15 · cited 1×
“However, a retrospective case-note review (Harris et al., 2010) reported that three out of 17 cases of paediatric OCD treated naturalistically with fluvoxamine developed behavioural disinhibition, including physical and verbal aggression and risk-taking behaviour.”
BackgroundA double-blind comparison of fluvoxamine and clomipramine in OCD
Rouillon, F. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)80473-2 · Cited by 10 · cited 2×
“Rouillon (1998) and Mundo (2001), in a larger study, showed equivalent efficacy for clomipramine and SSRIs at all visits and on all outcome measures.”
ResultKumar, S., Ng, B., & Howie, W. (2003) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2003.01107.x · Cited by 9 · cited 1×
“This may be particularly evident for clozapine (Sa et al., 2009), though there have also been reports of obsessive symptoms in patients with schizophrenia improving with clozapine treatment (Kumar et al., 2003) or with the addition of aripiprazole (Englisch et al., 2009).”
BackgroundMianserin Hydrochloride (Org GB 94) in the Treatment of Obsessional States
Väisänen, E., Ranta, P., Nummikko‐Pelkonen, A., & Tienari, P. (1977) · Journal of International Medical Research · doi:10.1177/030006057700500411 · Cited by 8
L-Tryptophan in obsessive compulsive disorder - a placebo controlled study
Montgomery, S., Fineberg, N. A., Montgomery, D., & Bullock, T. (1992) · European Neuropsychopharmacology · doi:10.1016/0924-977x(92)90241-y · Cited by 6 · cited 1×
“Preliminary reports hinting at the benefits for agents acting on serotonin, such as mianserin (Vïsänen et al., 1977) and the serotonin precursor l-tryptophan (Montgomery et al., 1992), are theoretically interesting.”
BackgroundSelf-citationDiniz, J. B., Pereira, C. A. D. B., Shavitt, R. G., & Miguel, E. C. (2011) · F1000Research · doi:10.7490/f1000research.1197.1 · Cited by 5
Akram, Y. (2008) · BMJ · doi:10.1136/bmj.39450.697245.ce · Cited by 5
Citalopram versus clomipramine in double-blind therapy of obsessive-compulsive disorder
Pidrman, V., & Tuna, I. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)80484-7 · Cited by 4
Research works printed but not linked: 18
- Eser D, 2010, Core Evidence, 4, 171
- Fernandez CE, 1967, Actas Luso-Españolas de Neurología, Psiquiatría y Ciencias Afines, 26, 119
- Feusner JD, 2009, Psychopharmacological Bulletin, 42, 81
- Foa EB, 1987, Psychopharmacology Bulletin, 23, 8
- Freeman CPC, 1994, Journal of Clinical Psychiatry, 55, 301
- 10.1001/archpsyc.1990.01810180077011 · DOI · Paper page
- Greist JH, 1990, Journal of Clinical Psychiatry, 51, 292
- Leonard HL, 1988, Psychopharmacology Bulletin, 24, 93
- Miguel EC, 2010, American College of Neuropsychopharmacology, 49th Annual Meeting
- Pigott TA, 1992, New Research Program and Abstracts of the 145th Annual Meeting of the American Psychiatric Association
- Ravizza L, 2001, Fifth International Obsessive Compulsive Disorder Conference
- Smeraldi E, 1992, New Trends in Experimental and Clinical Psychiatry, 8, 63
- Szegedi A, 1996, Journal of Clinical Psychiatry, 57, 257
- Ushijima S, 1997, Japanese Journal of Neuropsychopharmacology, 19, 603
- Wagner KD, 1999, 39th Annual Meeting of the New Clinical Drug Evaluation Unit
- Weissman MM, 1994, Journal of Clinical Psychiatry, 55, 5
- Wheadon D, 1993, 32nd Annual Meeting of the American College of Neuropsychopharmacology
- Yaryura-Tobias JA, 1976, Current Therapy Research, 20, 541
Cited by
The role of habit in compulsivity
Gillan, C. M., Robbins, T. W., Sahakian, B. J., van den Heuvel, O. A., & van Wingen, G. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.12.033 · Cited by 292
“The main pharmacological treatment for OCD are antidepressant drugs, including selective serotonin reuptake inhibitors (SSRIs) (Fineberg et al., 2013).”
BackgroundDold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
Fineberg, N. A., Apergis-Schoute, A. M., Vaghi, M. M., Banca, P., Gillan, C. M., Voon, V., Chamberlain, S. R., Cinosi, E., Reid, J., Shahper, S., et al. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx088 · Cited by 183
“Of considerable interest, subthreshold OCD is found to be extremely common and such cases share a similar age of onset and symptom trajectory as OCD, suggesting a natural continuum of compulsive behavior exists affecting as many as 20% of the general population (Fineberg et al., 2013b).”
InfluentialSelf-citationBandelow, B., Baldwin, D., Abelli, M., Altamura, C., Dell’Osso, B., Domschke, K., Fineberg, N. A., Grünblatt, E., Jarema, M., Maron, E., et al. (2016) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1181783 · Cited by 164
“Interest in the dopaminergic system came from the treatment of OCD using antipsychotics as augmenting agents alongside SSRIs (Fineberg et al. 2013).”
BackgroundInfluentialSelf-citationVeale, D., Miles, S., Smallcombe, N., Ghezai, H., Goldacre, B., & Hodsoll, J. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0317-5 · Cited by 162
“drugs as a class for augmentation of SSRI treatment resistant OCD [5,6].”
Background
Metadata
- Authors
- Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I.
- Affiliations
- Queen Elizabeth II Hospital (GB)
- Surrey and Borders Partnership NHS Foundation Trust (GB)
- Venue
- Australian & New Zealand Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2012-11-02
- Volume
- 47
- Issue
- 2
- Pages
- 121-141
- ISSN
- 0004-8674 (ISSN-L)
- 1440-1614
- OpenAlex
- W2150547685
- Cited by
- 122
- References
- 189
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 7 · 2023: 7 · 2022: 6 · 2021: 6 · 2020: 9 · 2019: 7 · 2018: 9 · 2017: 10 · 2016: 5 · 2015: 18 · 2014: 15 · 2013: 12 · 2012: 2
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Australian & New Zealand Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- British Association for Psychopharmacology
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Keywords
- obsessive-compulsive disorder, pharmacotherapy, selective serotonin reuptake inhibitors, clomipramine, relapse, long-term treatment, health-related quality of life, serotonin receptor subtypes
- MeSH terms
- Clomipramine, Humans, Obsessive-Compulsive Disorder, Recurrence, Antipsychotic Agents, Selective Serotonin Reuptake Inhibitors, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.